These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31240706)

  • 21. Translocation and dissemination to target neurons of botulinum neurotoxin type B in the mouse intestinal wall.
    Connan C; Varela-Chavez C; Mazuet C; Molgó J; Haustant GM; Disson O; Lecuit M; Vandewalle A; Popoff MR
    Cell Microbiol; 2016 Feb; 18(2):282-301. PubMed ID: 26294282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins.
    Peng L; Berntsson RP; Tepp WH; Pitkin RM; Johnson EA; Stenmark P; Dong M
    J Cell Sci; 2012 Jul; 125(Pt 13):3233-42. PubMed ID: 22454523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro potency determination of botulinum neurotoxin B based on its receptor-binding and proteolytic characteristics.
    Wild E; Bonifas U; Klimek J; Trösemeier JH; Krämer B; Kegel B; Behrensdorf-Nicol HA
    Toxicol In Vitro; 2016 Aug; 34():97-104. PubMed ID: 27032463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of extracellular and intracellular potency of botulinum neurotoxins.
    Cai F; Adrion CB; Keller JE
    Infect Immun; 2006 Oct; 74(10):5617-24. PubMed ID: 16988237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.
    Weisemann J; Stern D; Mahrhold S; Dorner BG; Rummel A
    Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27196927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.
    Peng L; Tepp WH; Johnson EA; Dong M
    PLoS Pathog; 2011 Mar; 7(3):e1002008. PubMed ID: 21483489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical Analysis of Neuronal Cell and the Mouse Bioassay for Detection of Botulinum Neurotoxins.
    Pellett S; Tepp WH; Johnson EA
    Toxins (Basel); 2019 Dec; 11(12):. PubMed ID: 31817843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and characterization of a novel botulinum neurotoxin.
    Zhang S; Masuyer G; Zhang J; Shen Y; Lundin D; Henriksson L; Miyashita SI; Martínez-Carranza M; Dong M; Stenmark P
    Nat Commun; 2017 Aug; 8():14130. PubMed ID: 28770820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the functional activity of botulinum neurotoxin subtype B6.
    Kohda T; Nakamura K; Hosomi K; Torii Y; Kozaki S; Mukamoto M
    Microbiol Immunol; 2017 Nov; 61(11):482-489. PubMed ID: 28898517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons.
    Coffield JA; Yan X
    J Pharmacol Exp Ther; 2009 Jul; 330(1):352-8. PubMed ID: 19372387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of substrate recognition by the novel Botulinum Neurotoxin subtype F5.
    Guo J; Chan EW; Chen S
    Sci Rep; 2016 Jan; 6():19875. PubMed ID: 26794648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optogenetically controlled human functional motor endplate for testing botulinum neurotoxins.
    de Lamotte JD; Polentes J; Roussange F; Lesueur L; Feurgard P; Perrier A; Nicoleau C; Martinat C
    Stem Cell Res Ther; 2021 Dec; 12(1):599. PubMed ID: 34865655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comprehensive Structural Analysis of
    Gregory KS; Acharya KR
    Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of botulinum neurotoxins with synaptic vesicle protein complexes.
    Baldwin MR; Barbieri JT
    Toxicon; 2009 Oct; 54(5):570-4. PubMed ID: 19362106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Control of autophagosome axonal retrograde flux by presynaptic activity unveiled using botulinum neurotoxin type a.
    Wang T; Martin S; Papadopulos A; Harper CB; Mavlyutov TA; Niranjan D; Glass NR; Cooper-White JJ; Sibarita JB; Choquet D; Davletov B; Meunier FA
    J Neurosci; 2015 Apr; 35(15):6179-94. PubMed ID: 25878289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unique biological activity of botulinum D/C mosaic neurotoxin in murine species.
    Nakamura K; Kohda T; Shibata Y; Tsukamoto K; Arimitsu H; Hayashi M; Mukamoto M; Sasakawa N; Kozaki S
    Infect Immun; 2012 Aug; 80(8):2886-93. PubMed ID: 22665374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons.
    Kiris E; Burnett JC; Nuss JE; Wanner LM; Peyser BD; Du HT; Gomba GY; Kota KP; Panchal RG; Gussio R; Kane CD; Tessarollo L; Bavari S
    Neurotox Res; 2015 May; 27(4):384-98. PubMed ID: 25782580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response.
    Dolimbek BZ; Jankovic J; Atassi MZ
    Immunol Invest; 2002; 31(3-4):247-62. PubMed ID: 12472183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry.
    Karalewitz AP; Fu Z; Baldwin MR; Kim JJ; Barbieri JT
    J Biol Chem; 2012 Nov; 287(48):40806-16. PubMed ID: 23027864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P19 embryonal carcinoma cells exhibit high sensitivity to botulinum type C and D/C mosaic neurotoxins.
    Tsukamoto K; Arimitsu H; Ochi S; Nakamura K; Tanaka Y; Nuemket N; Taniguchi K; Kozaki S; Tsuji T
    Microbiol Immunol; 2012 Oct; 56(10):664-72. PubMed ID: 22738015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.